semaglutide and sleep issues Fatigue: Feeling Weak on Semaglutide Can New Weight Loss Drugs

In this episode of Peptides Explained, John Garrett, RN, breaks down: What AOD-9604 is and how it differs from full-length HGH Lipolysis, lipogenesis, and beta-3 adrenergic signaling Why animal studies looked promising What the early human trials showed Why the obesity-development program was discontinued Whether AOD-9604 raises IGF-1 Regulatory status, risks, unknowns, and anti-doping concerns A responsible framework for evaluating experimental fat-loss peptides The central takeaway: AOD-9604 has a plausible preclinical mechanism, but the available human evidence does not establish dependable, clinically meaningful fat loss

Some researchers interpreted these findings as a potential disease-modifying signal rather than simple symptomatic improvement

While these treatments are highly effective, experiencing GLP-1 fatigue is a recognised side effect, reported by around 1015% of patients in clinical trials compared with those taking a placebo

Factors such as insurance coverage, availability, side effect tolerance, and cost all play a role in the decision